Skip to main content
logo
Veradermics, Incorporated (MANE)
NYSE: MANE · Real-Time Price · USD
102.82
-2.50 (-2.37%)
Aug 21, 2026, 4:00 PM EDT - Market closed

Veradermics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Net Income
-92.68-70-26.49-16.49
Loss (Gain) From Sale of Investments
-0.39-0.56--
Stock-Based Compensation
9.891.440.250.21
Other Operating Activities
1.441.41.821.85
Change in Accounts Payable
5.39-0.120.651.35
Change in Other Net Operating Assets
-2.37-3.760.09-0.43
Operating Cash Flow
-78.3-71.6-23.69-13.51
Operating Cash Flow Growth
----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Capital Expenditures
-0.03-0.02--
Investment in Securities
-473.34-118.83--
Investing Cash Flow
-473.36-118.86--

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Long-Term Debt Issued
--8.51-
Long-Term Debt Repaid
---0.85-
Net Debt Issued (Repaid)
--7.66-
Issuance of Common Stock
683.720.16--
Other Financing Activities
27.67-0.45-0.28-0.04
Financing Cash Flow
862.4159.1460.4813.9

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Net Cash Flow
310.74-31.3236.790.39

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-78.33-71.63-23.69-13.51
Free Cash Flow Growth
----
Free Cash Flow Per Share
-4.84-96.14-32.14-18.33
Levered Free Cash Flow
--47.55-16.37-
Unlevered Free Cash Flow
--47.55-16.01-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Cash Interest Paid
--0.1-
Change in Working Capital
3.02-3.890.730.92
SEC Filings: 10-K · 10-Q